Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: Findings from cohort C of the OPAL phase 2 trial.
- DOI
- 10.1016/j.ygyno.2026.07.023
- Published
- 2026 Sep
- Container
- Gynecologic oncology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.ygyno.2026.07.023,
title = {Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: Findings from cohort C of the OPAL phase 2 trial.},
author = {Westin SN and Belotte J and Felicetti B and Aghera V and YoussefAgha A and Bakirtzi E and Ortiz AG and García AB and Provencher D and Vázquez RM and Cortijo LG and Zeng X and Silasi DA and Bradford LS and Musa FB and Chan JK and Liu JF and Rojas-Espaillat L},
year = {2026},
journal = {Gynecologic oncology},
doi = {10.1016/j.ygyno.2026.07.023},
url = {https://doi.org/10.1016/j.ygyno.2026.07.023}
}RIS
TY - JOUR TI - Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: Findings from cohort C of the OPAL phase 2 trial. AU - Westin SN AU - Belotte J AU - Felicetti B AU - Aghera V AU - YoussefAgha A AU - Bakirtzi E AU - Ortiz AG AU - García AB AU - Provencher D AU - Vázquez RM AU - Cortijo LG AU - Zeng X AU - Silasi DA AU - Bradford LS AU - Musa FB AU - Chan JK AU - Liu JF AU - Rojas-Espaillat L PY - 2026 JO - Gynecologic oncology DO - 10.1016/j.ygyno.2026.07.023 UR - https://doi.org/10.1016/j.ygyno.2026.07.023 ER -
APA
SN, W., J, B., B, F., V, A., A, Y., E, B., AG, O., AB, G., D, P., RM, V., LG, C., X, Z., DA, S., LS, B., FB, M., JK, C., JF, L., & L, R. (2026). Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: Findings from cohort C of the OPAL phase 2 trial.. Gynecologic oncology. https://doi.org/10.1016/j.ygyno.2026.07.023
Source records
- pubmed · retrieved 2026-09-25T22:09:50.309Z